title: Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns.
abstract: BACKGROUND
  Wound healing is a dynamic process that could be accelerated by growth factors. We investigated the effect of recombinant bovine basic fibroblast growth factor (rbFGF) on burn healing in a randomised placebo-controlled trial.
  
  
  METHODS
  We recruited 600 patients with superficial or deep second-degree burns. Patients received 150 AU/cm2 daily topical rbFGF (n=300) or placebo (n=300) plus vehicle. We assessed healing by photography, punch-biopsy, and clinical examination.
  
  
  RESULTS
  All patients treated with rbFGF had faster granulation tissue formation and epidermal regeneration than those in the placebo group. Superficial and deep second-degree burns treated with rbFGF healed in a mean of 9.9 (SD 2.5) days and 17.0 (4.6) days, respectively, compared with 12.4 (2.7) and 21.2 (4.9) days (p=0.0008 and p=0.0003, respectively). No adverse effects were seen locally or systemically with rbFGF.
  
  
  CONCLUSIONS
  rbFGF effectively decreased healing time and improved healing quality. Clinical benefits would be shorter hospital stays and the patient's skin quickly becoming available for harvesting and grafting.
authors.affiliation: 304th Hospital, Trauma Center of Postgraduate Medical College, Beijing, PR China.
authors.forename: X
authors.initials: X
authors.lastname: Fu
authors.forename: Z
authors.initials: Z
authors.lastname: Shen
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Xie
authors.forename: Z
authors.initials: Z
authors.lastname: Guo
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: Z
authors.initials: Z
authors.lastname: Sheng
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001706:Biopsy; D002056:Burns / Q000188:drug therapy* / Q000473:pathology; D002417:Cattle; D002648:Child; D004311:Double-Blind Method; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006097:Granulation Tissue / Q000187:drug effects / Q000473:pathology; D006801:Humans; D015601:Injury Severity Score; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects
chemical_list: C100666:KCB-1 protein, recombinant; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2